Water Vapor Ablation for Prostate Cancer: Long-Term Registry
Vanquish® Water Vapor Ablation for PrOstate CanceR: Long-Term Registry
Francis Medical Inc.
2,500 participants
Jun 5, 2026
OBSERVATIONAL
Conditions
Summary
The purpose of the registry is to evaluate real-world safety, efficacy, and patient reported outcomes among participants receiving Vanquish Water Vapor Ablation System therapy (Vanquish Therapy). This includes longitudinal assessment of patients who have received or will receive the therapy one or multiple times as part of routine clinical care and encompasses those who completed a company-sponsored Vanquish therapy study (as applicable).
Eligibility
Inclusion Criteria2
- Candidate for Vanquish therapy per physician discretion or participant has completed a company-sponsored Vanquish therapy study.
- Participant is willing and able to provide written informed consent.
Exclusion Criteria2
- Contraindications per the Vanquish IFU
- Previously participated in VAPOR 2 study and is not planning to receive further Vanquish therapy.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The Francis Medical, Inc. Vanquish Water Vapor Ablation Device ("Vanquish" or "Vanquish System") is a transurethral thermal water vapor ablation device. The Vanquish System is designed ablate prostate tissue, while minimizing side effects.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07455058